NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Stifel Nicolaus

Stifel Nicolaus began coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a note issued to investors on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $44.00 price target on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 118.25% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They set an “overweight” rating and a $42.00 price objective on the stock. Needham & Company LLC dropped their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, May 8th. Wall Street Zen upgraded NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Friday, May 30th. Scotiabank boosted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Finally, UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $43.00.

NewAmsterdam Pharma Trading Up 0.1%

Shares of NewAmsterdam Pharma stock opened at $20.16 on Tuesday. The stock’s fifty day moving average price is $17.82 and its 200-day moving average price is $20.86. The firm has a market cap of $2.26 billion, a P/E ratio of -10.72 and a beta of -0.03. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The business had revenue of $2.98 million for the quarter, compared to the consensus estimate of $1.46 million. Analysts forecast that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,135 shares of the stock in a transaction on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently modified their holdings of the stock. Legal & General Group Plc grew its position in NewAmsterdam Pharma by 24.8% during the 4th quarter. Legal & General Group Plc now owns 22,946 shares of the company’s stock worth $590,000 after purchasing an additional 4,556 shares during the last quarter. American Century Companies Inc. purchased a new position in shares of NewAmsterdam Pharma in the fourth quarter worth $8,907,000. Swiss National Bank lifted its stake in shares of NewAmsterdam Pharma by 105.1% during the fourth quarter. Swiss National Bank now owns 72,000 shares of the company’s stock worth $1,850,000 after buying an additional 36,900 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $80,000. Finally, Northern Trust Corp purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at $556,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.